Will U.S. adult obesity rate decrease by more than 1% in 2025? | Binary | | | 9 days ago | |
EMA confirms Ozempic-NAION link by end of 2025? | Binary | | | 10 days ago | |
Will Novo Nordisk announce a new Phase 3 trial for CagriSema by end of 2025? | Binary | | | 21 days ago | |
Will Novo Nordisk's CagriSema receive FDA approval by end of 2025? | Binary | | | 22 days ago | |
Semaglutide removed from FDA drug shortage list by June 30, 2024? | Binary | | | 22 days ago | |
Most prescribed diabetes drug in Europe by end of 2025? | Categorical | | | 28 days ago | |
What will be the outcome of RFK Jr.'s HHS Secretary nomination by March 31, 2025? | Categorical | | | 1 month ago | |
Will FDA issue warning or ban on compounded GLP-1 drugs by end of 2025? | Binary | | | 1 month ago | |
Will Zepbound price drop by 20% or more by June 30, 2025? | Binary | | | 1 month ago | |
Will Amaryllis Fox Kennedy be appointed Deputy Director of the CIA by June 30, 2025? | Binary | | | 1 month ago | |
Will Brazil distribute generic Ozempic in public clinics by June 2025? | Binary | | | 9 days ago | |
What new treatment application will Novo Nordisk or Eli Lilly announce for weight-loss drugs by end of 2025? | Categorical | | | 9 days ago | |
Will Eli Lilly surpass Novo Nordisk in obesity drug market share by end of 2025? | Binary | | | 21 days ago | |
Market leader in obesity drugs by market cap by end of 2025 | Categorical | | | 21 days ago | |
Will Novo Nordisk's market cap recover to pre-drop levels by June 30, 2025? | Binary | | | 21 days ago | |
Which company will lead the weight loss drug market by end of 2025? | Categorical | | | 22 days ago | |
Which company will lead the weight loss drug market by December 31, 2025? | Categorical | | | 22 days ago | |
Outcome of Novo Nordisk's next major obesity drug trial by December 31, 2025? | Categorical | | | 22 days ago | |
Which company will see the highest stock price increase in 2025 among major weight loss drug developers? | Categorical | | | 22 days ago | |
Will Novo Nordisk's stock recover to pre-announcement levels by December 31, 2025? | Binary | | | 22 days ago | |
Will Novo Nordisk announce a new CagriSema trial with improved results by June 30, 2025? | Binary | | | 22 days ago | |
Will Eli Lilly surpass Novo Nordisk in market capitalization by December 31, 2025? | Binary | | | 22 days ago | |
Will Novo Nordisk stock recover to $125 by June 30, 2025? | Binary | | | 22 days ago | |
FDA enforcement against 503(a) compounders for tirzepatide by February 29, 2024? | Binary | | | 22 days ago | |
FDA enforcement against 503(b) compounders for tirzepatide by March 31, 2024? | Binary | | | 22 days ago | |
Will Novo Nordisk's Odense facility create 400 permanent jobs by end of 2028? | Binary | | | 25 days ago | |
Will Novo Nordisk complete Odense facility construction by end of 2027? | Binary | | | 25 days ago | |
Novo Nordisk boosts Wegovy and Ozempic production by 30% by mid-2025? | Binary | | | 26 days ago | |
What will be Novo Nordisk's market share in anti-obesity drugs by 2025 end? | Categorical | | | 27 days ago | |
Will Novo Nordisk boost Wegovy and Ozempic production by 20% by mid-2025? | Binary | | | 27 days ago | |
What will be Novo Nordisk's revenue growth rate for 2025? | Categorical | | | 27 days ago | |
Will RFK Jr. initiate a CIA investigation into JFK's assassination by end of 2025? | Binary | | | 1 month ago | |
Will Ro-Lilly partnership boost Zepbound prescriptions by 50% by end of 2025? | Binary | | | 1 month ago | |
What market share will Zepbound achieve in US weight-loss market by end of 2025? | Categorical | | | 1 month ago | |
Will Zepbound receive FDA approval for expanded obesity treatment use by end of 2025? | Binary | | | 1 month ago | |
Will Zepbound become the leading weight-loss drug by US market share by end of 2025? | Binary | | | 1 month ago | |
What will be the primary barrier to weight-loss drug adoption in the U.S. by end of 2025? | Categorical | | | 9 days ago | |
Will U.S. grocery spending decrease by an additional 2% in 2025? | Binary | | | 9 days ago | |
Ozempic sales suspended in US or Europe over NAION concerns by end of 2025? | Binary | | | 10 days ago | |
Outcome of EMA investigation on Ozempic-NAION link by end of 2025 | Categorical | | | 10 days ago | |
Changes in Ozempic prescription guidelines by end of 2025 due to NAION | Categorical | | | 10 days ago | |
NAION cases linked to Ozempic in Denmark by end of 2025 | Categorical | | | 10 days ago | |
Novo Nordisk updates Ozempic warning label for NAION risk by end of 2025? | Binary | | | 10 days ago | |
What will be Novo Nordisk's market position in the obesity drug sector by the end of 2025? | Categorical | | | 21 days ago | |
Will CagriSema receive FDA approval by the end of 2025? | Binary | | | 21 days ago | |
Will Novo Nordisk's stock price recover to pre-announcement levels by March 31, 2025? | Binary | | | 21 days ago | |
Will Novo Nordisk announce a new weight loss target for CagriSema by the end of 2025? | Binary | | | 21 days ago | |
What will be Novo Nordisk's next strategic move post-CagriSema trial results by June 2025? | Categorical | | | 21 days ago | |
What will be the outcome of CagriSema trials in other regions by the end of 2025? | Categorical | | | 21 days ago | |
Next major Novo Nordisk obesity treatment announcement by end of 2025 | Categorical | | | 21 days ago | |
CagriSema weight loss percentage milestone in 2025 | Categorical | | | 21 days ago | |
How will Novo Nordisk's share price performance compare to Eli Lilly by end of 2025? | Categorical | | | 22 days ago | |
Will Novo Nordisk's stock price recover to pre-announcement levels by June 30, 2025? | Binary | | | 22 days ago | |
Will Eli Lilly's ZepBound have a higher market share than Novo Nordisk's CagriSema by end of 2025? | Binary | | | 22 days ago | |
What will Novo Nordisk do next with CagriSema by end of 2025? | Categorical | | | 22 days ago | |
Which company will release the next major obesity drug post-CagriSema trial by end of 2025? | Categorical | | | 22 days ago | |
Will Eli Lilly's obesity drug surpass CagriSema in market share by end of 2025? | Binary | | | 22 days ago | |
What will be identified as the primary reason for CagriSema's failure in future analyses by end of 2025? | Categorical | | | 22 days ago | |
What will Novo Nordisk's stock price be at the end of Q2 2025? | Categorical | | | 22 days ago | |
Will CagriSema achieve target weight loss in future Phase 3 trial by end of 2025? | Binary | | | 22 days ago | |
Primary reason for next FDA drug shortage announcement in 2025? | Categorical | | | 22 days ago | |
Next company after Eli Lilly with FDA drug shortage resolution by December 31, 2024? | Categorical | | | 22 days ago | |
Next drug removed from FDA shortage list in 2025? | Categorical | | | 22 days ago | |
Which rare disease treatment will Novo Nordisk get approved by end of 2025? | Categorical | | | 25 days ago | |
How will Novo Nordisk's Odense facility investment impact stock price by end of 2025? | Categorical | | | 25 days ago | |
What product types will Novo Nordisk's Odense facility produce by end of 2029? | Categorical | | | 25 days ago | |
Will Novo Nordisk start production at Odense facility by end of 2028? | Binary | | | 25 days ago | |
Novo Nordisk's stock vs. pharma indices performance by end of 2025? | Categorical | | | 26 days ago | |
Novo Nordisk integrates Catalent's capabilities by end of 2025? | Binary | | | 26 days ago | |
Novo Nordisk's Odense facility operational by end of 2025? | Binary | | | 26 days ago | |
Impact of Catalent acquisition on Novo Nordisk's diabetes market share by end of 2025? | Categorical | | | 26 days ago | |
Novo Nordisk's global pharma revenue rank by end of 2025? | Categorical | | | 26 days ago | |
What will cause a delay in Catalent acquisition finalization by 2024 end? | Categorical | | | 27 days ago | |
Will Novo Nordisk face legal challenges over Catalent deal by mid-2025? | Binary | | | 27 days ago | |
Will Novo Nordisk integrate Catalent's sites by end of 2025? | Binary | | | 27 days ago | |
Will Novo Nordisk launch a product using Catalent sites by end of 2025? | Binary | | | 28 days ago | |
Will Novo Nordisk face regulatory issues from Catalent acquisition by 2025? | Binary | | | 28 days ago | |
Will Novo Nordisk integrate Catalent sites by end of 2025? | Binary | | | 28 days ago | |
Novo Nordisk's market share change post-Catalent acquisition by 2025 | Categorical | | | 28 days ago | |
Novo Nordisk's revenue growth impact from Catalent acquisition in FY 2025 | Categorical | | | 28 days ago | |
Novo Nordisk's global ranking in pharma sector post-Catalent acquisition by 2025 | Categorical | | | 28 days ago | |
Primary reason for Ozempic prescription increase in Europe post-EMA update by June 2025? | Categorical | | | 28 days ago | |
Outcome of vision loss study related to Ozempic by end of 2025? | Categorical | | | 28 days ago | |
Novo Nordisk issues safety update or recall for Ozempic over vision loss by end of 2025? | Binary | | | 28 days ago | |
Mounjaro surpasses Ozempic in European diabetes treatment market share by end of 2025? | Binary | | | 28 days ago | |
Increase in Ozempic prescriptions in Europe post-EMA label update by June 2025? | Binary | | | 28 days ago | |
Who will launch public awareness campaigns about Ozempic by end of 2025? | Categorical | | | 28 days ago | |
What will Novo Nordisk do in response to the Ozempic study by end of 2025? | Categorical | | | 28 days ago | |
Will regulatory action be taken against Ozempic in Europe by end of 2025? | Binary | | | 28 days ago | |
Will the Ozempic-NAION study be peer-reviewed and published by June 2025? | Binary | | | 28 days ago | |
Will Novo Nordisk update Ozempic's safety information by June 2025? | Binary | | | 28 days ago | |
What will peer-reviewed studies conclude about Ozempic and NAION by end of 2025? | Categorical | | | 28 days ago | |
What will be the Nobel Laureates' stance on RFK Jr. after Senate decision by April 30, 2025? | Categorical | | | 1 month ago | |
What will be the major policy focus of RFK Jr. as HHS Secretary in 2025? | Categorical | | | 1 month ago | |
How many new partnerships will Eli Lilly form for Zepbound by end of 2025? | Categorical | | | 1 month ago | |
What will be the market share change between Zepbound and Wegovy by end of 2025? | Categorical | | | 1 month ago | |
Will Novo Nordisk announce a Wegovy successor trial with improved efficacy by end of 2024? | Binary | | | 1 month ago | |
What will be the average weight loss percentage in a new Zepbound trial by end of 2025? | Categorical | | | 1 month ago | |
In how many countries will Zepbound be approved for obesity treatment by end of 2025? | Categorical | | | 1 month ago | |
Which U.S. economic sector will weight-loss drugs impact most by end of 2025? | Categorical | | | 9 days ago | |